Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 20 citations · 19 references
MedicineOncologyPharmacotherapyChemotherapyHematologic OncologyMedical OncologyAntiviral PharmacotherapyAntiviral TherapyHematologic Malignancy TherapyInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentDirect-acting Antiviral AgentsDirect-acting AntiviralsNucleoside Analogue AntiviralsPost-treatment RelapseRelapsed Diffuse Large B-cell LymphomaSalvageSustained Virologic Response Duration
Recent studies have demonstrated feasibility and substantial benefit of direct-acting antivirals (DAAs) administration during or after first-line immune-chemotherapy (I-CT) in patients with hepatitis C virus (HCV)-positive diffuse large B-cell lymphomas (DLBCL). However, data on DAAs used during or after salvage treatments are still lacking. In this study we assessed clinical and virological outcome in 11 patients with relapsed (n = 7) or refractory (n = 4) HCV-positive DLBCL. DAAs were given either concurrently (n = 3) or subsequent (n = 8) to salvage I-CT. Most patients (10 of 11) received sofosbuvir-based regimens. All patients completed their planned courses of DAAs and achieved sustained virological response. DAAs were well tolerated, with no grade ≥2 adverse events. At a median follow-up of 3.6 years four patients died (4-year OS: 76%). In conclusion, we provide evidence that DAAs in HCV-positive relapsed/refractory DLBCL are extremely safe and effective, suggesting that they should be used if HCV eradication was not instituted before.
19